Effect of Extra-Virgin Olive Oil on Hand Foot Syndrome and hs-CRP in Patients Receiving Capecitabine: A Randomized Trial
Andayani YD, Saleh MI, Sudoyo AW, Ali Z, Legiran L, Partan RU, Yuristo E, Lubis FZ
Acta medica Indonesiana · 1 cita
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Universitas Sriwijaya
Según 1 financiador declarado.
Publicación
- Publicado
- 2023-10-01 · Acta Med Indones · vol. 55 · número 4 · págs. 396–402
- Editorial
- Interna Publishing
- Citado
- 1 cita · más que el 62% de estudios similares · 0.2× el promedio de su campo
- Referencias
- 0 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Chemotherapy-related skin toxicity · Cancer Treatment and Pharmacology · Chemotherapy-induced organ toxicity mitigation
- Palabras clave
- extra virgin olive oil, hand-foot syndrome, capecitabine, C-reactive protein, chemotherapy side effects, olive oil supplementation, anti-inflammatory activity, colorectal cancer, breast cancer
- MeSH
- humans, breast neoplasms, colorectal neoplasms, c-reactive protein, female, hand-foot syndrome, olive oil, capecitabine
8 autores
- Yenny Dian Andayani🇮🇩Sriwijaya University
- Mgs. Irsan Saleh
- Aru Wisaksono Sudoyo
- Zulkhair Ali
- Legiran Legiran
- Radiyati Umi Partan
- Eddy Yuristo
- Fadhyl Zuhry Lubis
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Hand Foot Syndrome (HFS) is a frequent adverse effect observed in patients undergoing capecitabine chemotherapy, often leading to treatment disruptions and dose adjustments. Elevated C-Reactive Protein (hs-CRP) levels have been associated with the development of HFS. This study aimed to assess the potential of unrefined Extra Virgin Olive Oil (EVOO) supplementation in mitigating HFS and hs-CRP elevation among individuals receiving capecitabine chemotherapy.
Methods
Between November 2022 and May 2023, forty-five eligible participants were enrolled in this randomized trial. Patients with advanced colorectal or breast cancer were randomly allocated into three groups: an intervention group receiving unrefined EVOO supplementation (30 mL per day) alongside capecitabine, a placebo group receiving refined extra light olive oil (ELOO) supplementation (30 mL per day) alongside capecitabine, and a control group receiving capecitabine alone. The masking of both placebo and intervention groups was ensured through identical packaging and instructions, maintaining participant and physician blindness to the assigned treatments. Randomization, achieved via computer-generated sequences, ensured even distribution among the three groups.
Results
HFS incidences were notably lower in the EVOO group (13.3%) compared to the placebo (66.7%) and control (80%) groups. Instances of Grade 2 or more severe HFS were observed in 20% of placebo and 40% of control group patients. No cases of severe HFS were reported in the EVOO group. Moreover, EVOO supplementation led to a significant reduction in hs-CRP levels when contrasted with the placebo and control groups. These findings suggest that EVOO may serve as a preventive measure against HFS and exhibit anti-inflammatory effects in patients undergoing capecitabine chemotherapy.
Conclusion
This study demonstrates the potential benefits of incorporating unrefined EVOO into the regimen of patients undergoing capecitabine chemotherapy. EVOO supplementation was associated with lower incidences of HFS and a reduction in hs-CRP levels, indicating its possible role in preventing HFS development and mitigating inflammation.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.